Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 14 art units • 19 examiners • 0 of 19 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Oregon Health & Science University has 20 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 20 distinct examiners and 15 distinct art units, showing broad allocation across the biotechnology and pharmaceutical examination structure.
TALBERT, ERIC MICHAEL is the busiest examiner, with 1 pending matter. Because each examiner is associated with only one pending matter, counsel will need matter-specific analysis rather than relying on a dominant examiner relationship.
The spread across art units also suggests that claim strategy, prior-art review, and response timing may need to be coordinated across multiple technical contexts. Portfolio oversight can still benefit from common internal guidance on disclosure, claim amendments, and consistency, even though the examination is not concentrated in one unit.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (26%) |
| §103 only | 4 (21%) |
| §102 only | 1 (5%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 6 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TALBERT, ERIC MICHAEL | 1 | 22.2% | +55.6% |
| RAPILLO, KRISTINE K | 1 | 28.8% | +26.9% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| NOGUEROLA, ALEXANDER STEPHAN | 1 | 82.8% | +3.0% |
| JORDAN, DANIEL JEFFERY | 1 | 56.5% | -18.3% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | VARADARAJ, ARCHANA | — |
| 18579830 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18622638 | TECHNIQUES TO GENERATE EXTERNAL LIMBUS-BASED CORNEOSCLERAL TOPOGRAPHY | JORDAN, DANIEL JEFFERY | 10d overdue |
| 17114433 | PREDICTING AND PREVENTING HYPOGLYCEMIA IN PATIENTS HAVING TYPE 1 DIABETES DURING PERIODS OF INCOGNIZANCE USING BIG DATA ANALYTICS AND DECISION THEORETIC ANALYSIS | GIRI, PURSOTTAM | 14d |
| 18858236 | MACHINE-LEARNING-BASED MEAL DETECTION AND SIZE ESTIMATION USING CONTINUOUS GLUCOSE MONITORING (CGM) AND INSULIN DATA | RAPILLO, KRISTINE K | 27d |
| 18044444 | STABILIZED HYDROPHOBIC NANOPARTICLES FOR ULTRASOUND IMAGING | MEJIAS, SAMANTHA LEE | 42d |
| 19089404 | SMART DRAIN COVER FOR SINK STERILIZATION AND MITIGATION OF AEROSOLIZED PATHOGENS | TALBERT, ERIC MICHAEL | — |
| 18834945 | METHODS AND SYSTEMS FOR SORTING PARTICLES IN FLUIDS | NOGUEROLA, ALEXANDER STEPHAN | — |
| 18292884 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | GUSSOW, ANNE | — |
| 18290740 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | STEELE, AMBER D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18858236 | MACHINE-LEARNING-BASED MEAL DETECTION AND SIZE ESTIMATION USING CONTINUOUS GLUCOSE MONITORING (CGM) AND INSULIN DATA | RAPILLO, KRISTINE K | 27d |
| 19089404 | SMART DRAIN COVER FOR SINK STERILIZATION AND MITIGATION OF AEROSOLIZED PATHOGENS | TALBERT, ERIC MICHAEL | — |
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | VARADARAJ, ARCHANA | — |
| 18292884 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | GUSSOW, ANNE | — |
| 18290755 | Self-assembling nanomaterial for the detection, imaging, or treatment of cancer | DONOHUE, SEAN R | — |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| 1658 | 2 |
| 1626 | 2 |
| 2872 | 2 |
| 1758 | 1 |
| 3682 | 1 |
| 1795 | 1 |
| 1685 | 1 |
| 1622 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19089404 | SMART DRAIN COVER FOR SINK STERILIZATION AND MITIGATION OF AEROSOLIZED PATHOGENS | TALBERT, ERIC MICHAEL | 1758 | §103 | Non-Final OA | — | Pending | Mar 25, 2025 |
| 18858236 | MACHINE-LEARNING-BASED MEAL DETECTION AND SIZE ESTIMATION USING CONTINUOUS GLUCOSE MONITORING (CGM) AND INSULIN DATA | RAPILLO, KRISTINE K | 3682 | §101§103 | Non-Final OA | 27d | Pending | Oct 18, 2024 |
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | VARADARAJ, ARCHANA | 1658 | §103 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18795621 | DERIVATIVES OF SOBETIROME | JACKSON, SHAWQUIA | 1626 | §112Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18834945 | METHODS AND SYSTEMS FOR SORTING PARTICLES IN FLUIDS | NOGUEROLA, ALEXANDER STEPHAN | 1795 | §102§103 | Final Rejection | — | Pending | Jul 31, 2024 |
| 18622638 | TECHNIQUES TO GENERATE EXTERNAL LIMBUS-BASED CORNEOSCLERAL TOPOGRAPHY | JORDAN, DANIEL JEFFERY | 2872 | §102§103 | Final Rejection | 10d overdue | Pending | Mar 29, 2024 |
| 18292884 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | GUSSOW, ANNE | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18290740 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | STEELE, AMBER D | 1658 | §101§102§103§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18290755 | Self-assembling nanomaterial for the detection, imaging, or treatment of cancer | DONOHUE, SEAN R | 1618 | §102§103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18579830 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18575219 | WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING | WESTERBERG, NISSA M | 1618 | §102DP | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18548864 | MOLECULAR BARCODES AND RELATED METHODS AND SYSTEMS | PHAM, KHAI QUYNH TIEN | 1684 | §102§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18269150 | ANTIBACTERIAL ESTER-FREE MONOMERS FOR DENTAL ADHESIVES | KELLY-O'NEILL, YOLANDA LYNNETTE | 1764 | §103 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18129767 | DIAGNOSTIC CLASSIFICATION OF CORNEAL DISEASES BASED ON ARTIFICIAL INTELLIGENCE | DINH, JACK | 2872 | §102§103 | Non-Final OA | — | Pending | Mar 31, 2023 |
| 18122605 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | AGUIRRE, AMANDA L | 1626 | §102 | Final Rejection | — | Pending | Mar 16, 2023 |
| 18044444 | STABILIZED HYDROPHOBIC NANOPARTICLES FOR ULTRASOUND IMAGING | MEJIAS, SAMANTHA LEE | 1618 | §102§103 | Final Rejection | 42d | Pending | Mar 08, 2023 |
| 17909908 | MECHANISTIC BIOMARKER FOR PREDICTING THE SURVIVAL OF PANCREATIC CANCER PATIENTS | TSAY, MARSHA M | 1656 | §101§112 | Final Rejection | — | Pending | Sep 07, 2022 |
| 17786186 | MULTI-SPECIFIC T CELL RECEPTORS | PETERS, ALEC JON | 1641 | §103DP | Final Rejection | 73d overdue | Pending | Jun 16, 2022 |
| 17114433 | PREDICTING AND PREVENTING HYPOGLYCEMIA IN PATIENTS HAVING TYPE 1 DIABETES DURING PERIODS OF INCOGNIZANCE USING BIG DATA ANALYTICS AND DECISION THEORETIC ANALYSIS | GIRI, PURSOTTAM | 2186 | §101§102§103 | Non-Final OA | 14d | Pending | Dec 07, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOregon Health & Science University has 19 pending office actions as of October 2026, spread across 14 art units and 19 examiners.
Eric Michael Talbert has the most, with 1 of Oregon Health & Science University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
